Clinical trials
Phase 3 Adenoma, Islet Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
3 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2018 | 1 |
| 2022 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 1 |
| RayzeBio, Inc. | 1 |
| Rezolute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adenoma, Islet Cell | 3 |
| Neuroendocrine Tumors | 3 |
| Carcinoid Tumor | 1 |
| Fibrosarcoma | 1 |
| Hyperinsulinism | 1 |
| Hypoglycemia | 1 |
| Insulinoma | 1 |
| Liposarcoma | 1 |
| Neoplasms | 1 |
| Neuroectodermal Tumors, Primitive | 1 |
Trials
Showing 1 to 3 of 3. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.